MedTrace Logo

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

NCT06479863 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-01-16

No results posted yet for this study

Summary

To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM

Conditions

  • Sporadic Inclusion Body Myositis (sIBM)
  • Idiopathic Inflammatory Myopathies

Interventions

COMBINATION_PRODUCT

Pozelimab/Cemdisiran

Patients to receive Pozelimab 200mg/Cemdisiran 200 mg SC injections every 4 weeks for 104 weeks

Sponsors & Collaborators

Principal Investigators

  • Yessar Hussain, MD · Austin Neuromuscular Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-08
Primary Completion
2027-05-30
Completion
2027-08-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06479863 on ClinicalTrials.gov